AMH and ovarian carcinoma: evaluated the AMH level in patients with AGCT and other types of ovarian cancers and confirmed that AMH is a specific and sensitive serum marker for the diagnosis of AGCT and monitoring both AMH and inhibin B during follow-up of a patient with AGCT improves the detection of recurrent disease (14).The absence of inhibin measurement is one of the limitations of our study, combined testing with AMH and inhibin B in such patients should be recommended.